Based on mIHC assay, we revealed abundant CD83+ and CD86+ antigen-presenting cells within peritumoral stroma of pre- and post-treatment samples of responders (Figure 5A, S9A-B, S9D), indicative of enhanced anti-tumor immunity. This evidence concerns the gene CD86 and neoplasm.